ECM
OMED

Endurant Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Endurant Capital Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-219,114
Closed -$465K – 83
2018
Q3 		$465K Buy
+219,114
New +$525K 0.21% 63
2018
Q1 		– Sell
-139,100
Closed -$570K – 91
2017
Q4 		$570K Buy
+139,100
New +$605K 0.17% 69

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Endurant Capital Management's OMED Position: Q4 2018 in Review

Endurant Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 219,114 shares — an estimated $465K sold.

Endurant Capital Management first reported a position in OMED in Q4 2017 and held it in 2 quarters. The position peaked at $570K in Q4 2017. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Endurant Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Endurant Capital Management sold 219,114 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $465K.
  • Endurant Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Endurant Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $570K in Q4 2017.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Endurant Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.